Advertisement

Molecular and Cell Biology of Human Gene Therapeutics

  • George Dickson

Part of the Molecular and Cell Biology of Human Diseases Series book series (volume 20)

Table of contents

  1. Front Matter
    Pages i-xv
  2. Ariberto Fassati, Matthew G. Dunckley, George Dickson
    Pages 1-19
  3. Martin G. Lee, Eric J. Kremer, Michel Perricaudet
    Pages 20-32
  4. Joseph Glorioso, Mary Ann Bender, David Fink, Neal Deluca
    Pages 33-63
  5. Itaru Yanagihara, Yasufumi Kaneda, Koji Inui, Shintaro Okada
    Pages 64-82
  6. Dominic J. Wells
    Pages 83-103
  7. Stewart A. Fabb, Jiannis Ragoussis
    Pages 104-124
  8. Donald W. Moorman, Kenneth W. Culver
    Pages 125-139
  9. John Bridgewater, Mary Collins
    Pages 140-156
  10. Christine Kinnon
    Pages 157-174
  11. Marinee K. L. Chuah, Thierry Vandendriessche, Richard A. Morgan
    Pages 175-194
  12. Clay Smith, Bruce A. Sullenger
    Pages 195-236
  13. Samuel C. Wadsworth, Alan E. Smith
    Pages 237-251
  14. Christopher H. Evans, Paul D. Robbins
    Pages 252-260
  15. George Dickson, Susan C. Brown
    Pages 261-280
  16. Howard Prentice, Keith A. Webster
    Pages 281-300
  17. Pedro R. Lowenstein
    Pages 301-349
  18. Olivier Danos, Jean-Michel Heard
    Pages 350-367
  19. Heather L. Davis, Robert G. Whalen
    Pages 368-387
  20. Back Matter
    Pages 388-403

About this book

Introduction

advanced metastatic disease of solid tumors, dictates that each tumor mass, indeed each individual metastasis, will have a unique antigen and cytokine environment and hence unique response to immune modu­ lation. A differential response to immunotherapy is thus inevitable. 4. Many of the human trials described are not randomized and report survival or response against historical controls. Most tumors described are immunogenic human tumors: renal cell cancer and melanoma are most common. In order to avoid the well-described inter-patient vari­ ation and rare incidence of spontaneous response among patient samples as well as selection bias and changes in practice over time, randomized trials are required. 5. Immunological treatment is unlike conventional chemotherapy in its endpoint. Most chemotherapeutic regimes require a complete response or a good partial response for cure or good palliation. There are now many cases where immunotherapy has provided long-term palliation without massive tumor reduction. Immunity may be stimulated to a degree which holds tumorigenicity in check and most importantly, pro­ vides good palliation for the patient in a manner that differs essentially from chemotherapy.

Keywords

Chromosom DNA gene therapy gene transfer genes

Editors and affiliations

  • George Dickson
    • 1
  1. 1.Department of BiochemistryRoyal Holloway, University of LondonEgham, SurreyUK

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-011-0547-7
  • Copyright Information Springer Science+Business Media Dordrecht 1995
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-010-4242-0
  • Online ISBN 978-94-011-0547-7
  • Buy this book on publisher's site
Industry Sectors
Pharma
Biotechnology